letrozole / Generic mfg. - LARVOL DELTA

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) (IGCS 2025) - P2/3 | " This international phase 2/3 trial randomly assigned (1:1) patients with recurrent LGSOC to receive either oral trametinib 2 mg once daily (n=130) or one of five SoC treatment options (n=130): intravenous paclitaxel 80 mg/m² by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m² once every 4 weeks; intravenous topotecan 4 mg/m² on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. At the time of the final analysis, 29 (22.3%) patients in the trametinib arm and 15 (11.5%) patients in the SoC arm remained alive. The median OS was 36.4 months in the trametinib arm versus 29.8 months in the SoC arm (HR 0.68; 95% CI 0.49-0.94; p=0.018, 1-sided), despite the fact that 72% of patients in the SoC arm crossed over to trametinib following progression. In the 93 SoC patients who crossed over to trametinib the median PFS..."

Clinical • Late-breaking abstract • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Identification of CA2 as a potential candidate gene involved in the therapeutic effect of Huatan Huoxue decoction on polycystic ovary syndrome: An integrated study of network pharmacology, Mendelian randomization, and experimental validation. (PubMed, J Food Drug Anal) - "Experimental validation was performed using a letrozole-induced PCOS rat model treated with HTHXD, with key targets assessed via quantitative PCR (qPCR) and immunohistochemical staining...CA2 expression was significantly upregulated in PCOS ovarian tissue (P < 0.0001), and markedly reduced after HTHXD treatment, consistent with immunohistochemical findings. CA2 may serve as a potential candidate gene associated with the therapeutic response to HTHXD in PCOS, with tanshindiol B and crocetin as major active components."

Journal • Polyendocrine Metabolic Ovarian Syndrome • CASP3 • SNCA

Diagnostic Discordance in Recurrent Pregnancy Loss: Hysteroscopy Resolves Ultrasound-MRI Disagreement in Septate Uterus, but Concurrent Ovulation Induction Precludes Causal Attribution of the Reproductive Outcome. (PubMed, Clin Case Rep) - "Following septoplasty and subsequent ovulation induction with letrozole, she conceived and delivered a healthy male infant at term by cesarean section...Second-look hysteroscopy was not performed, so restoration of a normal cavity was never objectively confirmed and residual septum or intrauterine adhesions could not be excluded before conception. This case demonstrates the diagnostic value of hysteroscopy in resolving discordant imaging while emphasizing that the outcome must not be attributed to septoplasty alone."

Journal • Gynecology • Polyendocrine Metabolic Ovarian Syndrome

Comparison of live birth rates between calorie-restricted diet and metformin prior to ovulation induction therapy in women with polycystic ovary syndrome and overweight/obesity: a protocol for a multicenter, randomized comparative effectiveness trial. (PubMed, Front Public Health) - P=N/A | "Whilst Guidelines recommend Letrozole in first line ovulation induction (OI), therapeutic interventions to optimise endocrine and metabolic PCOS features prior to OI have not been adequately researched despite potential to improve live birth and pregnancy outcomes. Early therapeutic intervention holds significant potential to disrupt the pathophysiological cycle characterized by hyperandrogenism, excessive adiposity, and insulin resistance for improving fertility and pregnancy outcomes. ClinicalTrials.gov, identifier NCT06049186."

Clinical protocol • HEOR • Journal • Genetic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome

Sequential vs. Combined Letrozole and Methotrexate for Tubal Ectopic Pregnancy. (clinicaltrials.gov) - P2/3 | N=144 | Active, not recruiting | Sponsor: Benha University

New P2/3 trial

KANDELA-302: A Phase 3, Global, Open-Label, Randomized Study of the Selective CDK4 Inhibitor BGB-43395 + Letrozole vs CDK4/6 Inhibitors (CDK4/6i) + Letrozole for First-Line (1L) Treatment (Tx) of Advanced or Metastatic HR+/HER2− Breast Cancer (BC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Letrozole in heavily pretreated recurrent ovarian cancer: the randomized phase III multicentre MITO 32 study. (ESMO 2026) - No abstract available

Clinical • P3 data • Oncology • Ovarian Cancer • Solid Tumor

Final Analysis of NRG Oncology/NSABP B-42, a Randomized, Double-blinded, Placebo-controlled Trial of Extended Letrozole in Postmenopausal Women with Hormone-receptor Positive Breast Cancer Who Have Completed Previous Adjuvant Therapy with an Aromatase Inhibitor (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). (PubMed, J Clin Oncol) - "Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype."

Journal • P2 data • Breast Cancer • Fallopian Tube Cancer • Hematological Disorders • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Low Grade Serous Carcinoma • Neutropenia • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • ER

Severe Delayed Ribociclib-Induced Liver Injury Despite Prolonged Drug Interruption (ACG 2026) - "She had been receiving ribociclib with letrozole & leuprolide since Oct 2025. Although hepatotoxicity from CDK4/6 inhibitors is recognized, progression after prolonged drug interruption is uncommon and warrants vigilant monitoring. Figure: Trend of Liver Function Tests and Bilirubin during Hospitalization Figure: Laboratory values during the admission"

Breast Cancer • Hepatitis B • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Infectious Disease • Liver Failure • Pancreatitis • Solid Tumor • ER • HER-2 • PGR

Late, Solitary Pancreatic Metastasis Presenting Nearly 15 Years After Treatment for Renal Cell Carcinoma (ACG 2026) - "She received bilateral mastectomy and adjuvant letrozole in November 2019...She was started on nivolumab plus ipilimumab in January 2026 and completed four cycles through March 2026...In the United States, guidelines for monitoring RCC recommend at least annual imaging for up to the first 5 years after partial or radical nephrectomy, but can be extended as clinically indicated; the median time from initial treatment to pancreatic metastases is 6-10 years, which can be long after monitoring has been discontinued. In patients with a history of RCC, isolated pancreatic metastases should spark concern for possible recurrence."

Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Nephrology • Nicotine Addiction • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Tobacco Addiction • ER • HER-2 • PAX8

A Bleeding Ulcer That Wasn't: Gastric Metastasis From Invasive Ductal Breast Carcinoma (ACG 2026) - "Her oncologic course was marked by axillary nodal recurrence in 2017, followed by progressive metastatic disease involving lung, bone, liver, and brain, treated with anastrozole, letrozole, fulvestrant/everolimus, alpelisib, trastuzumab deruxtecan, and elacestrant. Gastroenterologists evaluating GI bleeding in patients with breast cancer history should pursue targeted biopsy with breast-directed immunohistochemistry, as accurate classification carries direct therapeutic implications. Figure: Endoscopic findings showing a 2.5 cm ulcer on the greater curvature of the proximal body and multiple additional ulcers up to 1.5 cm along the antrum, distal body, and proximal body of the stomach."

Breast Cancer • Gastric Cancer • Gastrointestinal Disorder • HER2 Positive Breast Cancer • Oncology • Peptic Ulcer • Solid Tumor • CDH1 • GATA3 • PGR

Metastatic Breast Carcinoma Unveiled by Endoscopy After a Positive Outpatient FOBT (ACG 2026) - "Patient was started on targeted therapy and hormone therapy with abemaciclib and letrozole and successfully achieved remission of disease on repeat PET scan. Figure: Figure 1 Colon biopsy revealed carcinoma with lobular and signet ring features (arrows), consistent with metastatic lobular carcinoma of the breast. Figure: Figure 2 Stomach biopsy showing carcinoma with lobular and signet ring features, consistent with metastatic lobular carcinoma of the breast."

Clinical • Metastases • Breast Cancer • Colorectal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

Invasive Lobular Carcinoma With Metastasis to the Colon: An Oncologic Anomaly (ACG 2026) - "The patient was already receiving letrozole and ribociclib therapy, and was referred to surgical oncology. This case highlights the importance of having high clinical suspicion in a patient with ILC who has the presence of GI symptoms. No matter how nonspecific the symptoms may be, there could be an underlying metastatic lesion waiting to be discovered."

Breast Cancer • CNS Disorders • Colorectal Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDX2 • GATA3 • HER-2 • NKX2-1 • PAX8 • WT1

Cribriform-morular variant of thyroid carcinoma with aggressive behavior: new successful therapeutic approaches (ETA 2026) - "The use of lenvatinib followed by letrozole combined with goserelin yielded a reduction in pulmonary metastases in aggressive CMV-TC. The underlying molecular mechanisms are currently under investigation."

Gastrointestinal Disorder • Genetic Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • APC • BRAF • MUTYH • NRAS • PGR • TERT • TG

Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer. (PubMed, Clin Cancer Res) - "Lenvatinib plus letrozole had manageable toxicity, with target engagement and preliminary antitumor activity observed, supporting further assessment in randomized studies."

Journal • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

RETRACTION: Reproductive Outcome after Letrozole versus Laparoscopic Ovarian Drilling for Clomiphene-Resistant Polycystic Ovary Syndrome. (PubMed, Int J Gynaecol Obstet) - "Without an adequate explanation from the authors or the study data to confirm the data and results, the editors consider the data and conclusions to be unreliable. Therefore, the article must be retracted."

Journal • Gynecology • Obstetrics • Polyendocrine Metabolic Ovarian Syndrome

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58. (ASCO 2023) - P3 | "HER2-E cohort will randomized pts 1:1 to RIB+ET (letrozole or fulvestrant) or PAL+ET. As per recent protocol amendment, BL cohort pts will be treated with paclitaxel plus tislelizumab, an anti PD-1 monoclonal antibody, pts may be offered to try RIB + ET first, and will remain eligible for paclitaxel + tislelizumab upon progression...HARMONIA will recruit in Spain (55 sites), Portugal (5), and US (35) within SOLTI & AFT network. Clinical trial information: NCT05207709."

Clinical • Head-to-Head • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC) (ESMO-BC 2023) - "Background Outcome of patients (pts) w/ stage I node neg HER2+ treated w/ wkly paclitaxel x 12 doses and trastuzumab x 1yr is excellent (10yr RFS 96%)...Three received tamoxifen and 3 letrozole...Conclusions Neoadjuvant zanidatamab for 3 months showed significant efficacy, (pCR/RCB-1 64%) w/ acceptable safety profile in pts w/ stage I node neg HER2+ BC. The trial is ongoing and has been modified to increase treatment duration to 5mths (10 cycles)."

Clinical • Acne Vulgaris • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CD4 • HER-2

PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study (SABCS 2023) - "Extended follow-up analysis from PARSIFAL study confirms no major differences between LET or FUL when combined with PAL. mPFS and mOS results are consistent with those reported in other first-line trials involving different CDK4/6i. Progression within the first year of first-line CDK4/6i-based regimen for HR+/HER2- ABC pts may be prognostic of less favorable outcomes."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. (PubMed, Lancet Oncol) - P1b | "Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the published results for standard-of-care therapies and had an acceptable safety profile."

Combination therapy • Journal • Metastases • P1 data • Breast Cancer • Dental Disorders • Diabetes • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • Stomatitis • HER-2 • PIK3CA

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. (ASCO 2024) - P3 | "Background: NATALEE assessed ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with HR+/HER2− EBC at increased risk of recurrence, including pts with N0 disease, and showed a statistically significant invasive disease-free survival (iDFS) benefit... Pts with stage II/III HR+/HER2− EBC were randomized (R) 1:1 to RIB 400 mg/d (3 wk on/1 wk off for 36 mo) + NSAI (letrozole or anastrozole for ≥60 mo) or NSAI alone. Men and premenopausal women received goserelin... This analysis showed a consistent efficacy benefit and manageable safety profile of RIB + NSAI vs NSAI alone in pts with N0 disease in NATALEE. The 3y iDFS, DDFS, and DRFS rates in the control arm at this early follow-up underscore the risk of recurrence for the N0 subgroup. These findings support the use of RIB in pts with HR+/HER2− EBC at increased risk of recurrence, including pts with N0 disease."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial (ESMO 2022) - P3 | "Clinical trial identification NCT03966898. Conclusions Adding dalp to letrozole/anastrozole significantly prolonged PFS in HR+/HER2- ABC, with manageable toxicities. Dalp is the 4 th CDK4/6 inhibitor showing survival benefit with letrozole or anastrozole in untreated HR+/HER2- ABC, or with fulvestrant in pretreated HR+/HER2- ABC, in addition to palbociclib, ribociclib and abemaciclib."

Clinical • Late-breaking abstract • P3 data • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. (PubMed, Ann Oncol) - "Abemaciclib combined with an NSAI resulted in clinically meaningful improvement in median OS (ITT: 13.1 months; sVD: 14.9 months) in patients with HR+ HER2- ABC; however, statistical significance was not reached."

Clinical • Journal • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2